23 december 2013: lees ook dit artikel: dasatinib-toegevoegd-aan-femara-letrozole-verdubbelt-ziektevrije-tijd-voor-patienten-met-hormoongevoelige-her2-neu-negatieve-uitgezaaide-borstkanker
27 juni 2012: er is zoveel gepubliceerd over hormoonremmers, aromaseremmers enz. voor de behandeling van borstkanker dat het onmogelijk is dat allemaal hier te publiceren. Als u naar oncoline-borstkanker gaat dan staat daar in de NABON nota in ieder geval wat de huidige richtljnen zijn voor borstkanker, maar ook dat is geschreven in medische taal en zeer uitgebreid.
Dit artikel: Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors
geeft een Engelstalig overzicht van hormoontherapie en aromaseremmers bij borstkanker. Hier het abstract van dit artikel. Onderaan hebben we een referentielijst toegevoegd behorend bij dit artikel.
Source
SOD Malattie del Metabolismo Minerale ed Osseo, AOU Careggi, Florence, Italy.
Abstract
Breast cancer, mostly exhibiting an hormone-dependent pathogenesis, is a commonly diagnosed cancer in females.It is well known that sex steroids favor the process of carcinogenesis of breast tissue and anti-hormonal therapy of breast cancer aims to decrease the action of estrogens on this tissue. For this purpose, two different compounds are prevalently used: the Selective Estrogen Receptor Modulators, preventing the cancer cell to interact with estrogens, and Aromatase Inhibitors, inhibiting the tissue conversion of androgens into estrogens. Unfortunately, latter treatments negatively impact on bone mass leading to the onset of osteoporosis. For this purpose, we propose to build a database to afford, to store and analyze information about the effects of treatment with Selective Estrogen Receptor Modulators and/or Aromatase Inhibitors on bone metabolism in patients with breast cancer referred to Our Center. We will focus on the possibility of intervening to reduce the negative effects on bone both by the identification of modifiable risk factors and administration of specific therapies, in order to create a therapeutic, diagnostic standard workup for these diseases.
- PMID:
- 22461802
- [PubMed - in process]
- PMCID:
- PMC3230922
8 augustus 2005: Bron: Lancet 2005;366:431-433,455-462. en J Clin Oncol. 2005 Aug 1;23(22):5138-47. Epub 2005 Jul 11 en Medscape
Vrouwen met vroeg gediagnosteerde borstkanker en daaraan geholpen en die na twee jaar overstappen van Tamoxifen naar Arimidex verminderen daarmee significant de kans op een recidief blijkt uit twee grote gerandomiseerde studies gepubliceerd in the Lancet en Clinical Oncology. In 1 studie gepubliceerd in The Lancet werden twee groepen gevormd van ca. 1600 vrouwen en in de groep die alleen Tamoxifen gebruikte waren er na een follow-up van 28 maanden 67 vrouwen met een recidief uit de Arimidex groep en 110 vrouiwen met een recidief in de Tamoxifen groep (hazard ratio 0.60 na 3 jaar, p = 0.0009). Het absolute verschil tussen de Tamoxifen groep en Arimidex groep op een drie jaar ziektevrije tijd was slechts 3,1 % maar dit cijfer is misleidend aldus de onderzoekers omdat jarenlange ziektevrije overlevingscijfers sowieso bij deze groep vrouwen erg hoog ligt. Bij de Arimidex groep deden zich wel meer botbreuken voor dan in de Tamoxifen groep , maar is naar wij weten te voorkomen met bv. Zometa of andere botversterkende middelen. De resultaten zijn onafhankelijk van tumorstadium, hormoongevoeligheid en al of niet klieruitzaaiingen. De studie uit Clinical Oncology bevestigt de studieresultaten uit The Lancet. Achtereenvolgens het studie abstract uit Clinical Oncology, een studie abstract uit The Lancet van januari 2005 met zelfde resultaten,
J Clin Oncol. 2005 Aug 1;23(22):5138-47. Epub 2005 Jul 11.
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the italian tamoxifen anastrozole trial.
Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P.
National Cancer Research Institute and the University of Genoa, Italy, Largo R. Benzi 10, 16132 Genoa, Italy; e-mail: f.boccardo@unige.it.
PURPOSE Tamoxifen, which is actually the gold standard adjuvant treatment in estrogen receptor-positive early breast cancer, is associated with an increased risk of endometrial cancer and other life-threatening events. Moreover, many women relapse during or after tamoxifen therapy because of the development of resistance. Therefore new approaches are required.
PATIENTS AND METHODS We conducted a prospective randomized trial to test the efficacy of switching postmenopausal patients who were already receiving tamoxifen to the aromatase inhibitor anastrozole. After 2 to 3 years of tamoxifen treatment, patients were randomly assigned either to receive anastrozole 1 mg/d or to continue receiving tamoxifen 20 mg/d, for a total duration of treatment of 5 years. Disease-free survival was the primary end point. Event-free survival, overall survival, and safety were secondary end points. Results Four hundred forty-eight patients were enrolled. All women had node-positive, estrogen receptor-positive tumors. At a median follow-up time of 36 months, 45 events had been reported in the tamoxifen group compared with 17 events in the anastrozole group (P = .0002). Disease-free and local recurrence-free survival were also significantly longer in the anastrozole group (hazard ratio = 0.35; 95% CI, 0.18 to 0.68; P = .001 and HR = 0.15; 95% CI, 0.03 to 0.65; P = .003, respectively). Overall, more adverse events were recorded in the anastrozole group compared with the tamoxifen group (203 v 150, respectively; P = .04). However, more events were life threatening or required hospitalization in the tamoxifen group than in the anastrozole group (33 of 150 events v 28 of 203 events, P = .04)
CONCLUSION Switching to anastrozole after the first 2 to 3 years of treatment is well tolerated and significantly improves event-free and recurrence-free survival in postmenopausal patients with early breast cancer.
PMID: 16009955 [PubMed - in process]
Lancet. 2005 Jan 1-7;365(9453):60-2.
Comment in:
Lancet. 2005 Apr 2-8;365(9466):1225; author reply 1225-6.
Lancet. 2005 Apr 2-8;365(9466):1225; author reply 1225-6.
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group.
Christie Hospital, Manchester, UK. anthony.howell@christie-tr.nwest.nhs.uk
The standard adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer is 5 years of tamoxifen, but recurrences and side-effects restrict its usefulness. The aromatase inhibitor anastrozole was compared with tamoxifen for 5 years in 9366 postmenopausal women with localised breast cancer. After a median follow-up of 68 months, anastrozole significantly prolonged disease-free survival (575 events with anastrozole vs 651 with tamoxifen, hazard ratio 0.87, 95% CI 0.78-0.97, p=0.01) and time-to-recurrence (402 vs 498, 0.79, 0.70-0.90, p=0.0005), and significantly reduced distant metastases (324 vs 375, 0.86, 0.74-0.99, p=0.04) and contralateral breast cancers (35 vs 59, 42% reduction, 12-62, p=0.01). Almost all patients have completed their scheduled treatment, and fewer withdrawals occurred with anastrozole than with tamoxifen. Anastrozole was also associated with fewer side-effects than tamoxifen, especially gynaecological problems and vascular events, but arthralgia and fractures were increased. Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer.
PMID: 15639680 [PubMed - indexed for MEDLINE]
Bron: Medscape:
Switch From Tamoxifen to Anastrozole Benefits Women With Early Breast Cancer
NEW YORK (Reuters Health) Aug 04 - Women with early breast cancer who have been taking tamoxifen for 2 years significantly reduce their risk of disease recurrence when they are switched to anastrozole for the next 3 years, according to analysis of data from two large prospective trials.
Other research has demonstrated anastrozole's improved efficacy and tolerability compared with tamoxifen as initial adjuvant therapy, Dr. Raimund Jakesz and colleagues note in their report, published in the August 6th issue of The Lancet. Whether patients on tamoxifen would benefit from replacing it with anastrozole after 2 years of treatment has not been established.
To explore this issue, Dr. Jakesz, from Vienna Medical University in Austria, and colleagues there and at the University of Frankfurt in Germany examined results of two trials in which postmenopausal women with resected hormone-sensitive early breast cancer had completed 2 years treatment with tamoxifen 20 to 30 mg daily.
The patients were randomly assigned to switch to anastrozole 1mg/day for 3 years (n = 1618) or to remain on tamoxifen (n = 1606). Events that were documented were local or distant metastasis or contralateral breast cancer.
During median follow-up of 28 months, 67 events were noted in the anastrozole group and 110 in the tamoxifen group (hazard ratio 0.60 at 3 years, p = 0.0009). The absolute benefit in event-free survival at 3 years was 3.1%
The advantages of swapping adjuvant treatment were not dependent on tumor grade, nodal status, age, or receptor positivity.
Anastrozole was associated with significantly more fractures (34 versus 16, p = 0.015) and fewer thromboses (3 versus 12, p = 0.034). There was also a trend towards fewer emboli and endometrial cancers in the anastrozole group.
"This combined analysis confirms that postmenopausal women who receive tamoxifen as adjuvant therapy should be switched to anastrozole after 2 years of treatment," Dr. Jakesz and his associates conclude.
The apparently small 3% absolute reduction in recurrence "is potentially misleading because of the generally good prognosis and low rates of relapse of most patients in these trials," Dr. Anthony Howell, from Christie Hospital NHS Trust in Manchester, UK, maintains in a related commentary.
"This does mean," he adds, "that some patients are unnecessarily treated with adjuvant endocrine therapy, indicating we need improved markers of the presence of important micrometastatic spread."
Lancet 2005;366:431-433,455-462
Bron: Public Relations van Astrazeneca:
Astrazenca stuurde ons een persbericht waarin o.a. volledige omschrijving van werking en toedieningsprocedure en eventuele bijwerkingen van Arimidex dat als volgt begint:
Onderzoek: veranderen van medicijn verkleint kans terugkeer borstkanker
Zoetermeer 5 augustus 2005 - De kans op terugkeer van borstkanker kan verkleind worden door een verandering van geneesmiddel. Vandaag publiceert het toonaangevende tijdschrift The Lancet (www.thelancet.com) dit goede nieuws. Dit is van groot belang voor de duizenden vrouwen in Nederland die tamoxifen gebruiken als behandeling voor hun borstkanker. Hieruit blijkt dat post-menopausale vrouwen die tamoxifen gebruiken minder kans hebben op de terugkeer van de borstkanker als ze na 2 jaar tamoxifen de therapie veranderen naar de aromataseremmer anastrozol (Arimidex®). De publicatie betreft een combinatie van gegevens van een Duitse (ARNO) en een Oostenrijkse (ABCSG) studie. De verandering van tamoxifen naar anastrozol resulteerde in een 40 % verlaging van het risico op de terugkeer van borstkanker, na een (mediane) follow-up van 28 maanden. Tevens resulteerde het in een 39% verlaging van het risico op uitzaaiingen.
Database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. [PubMed]
2. American Cancer Society. 2008. Cancer Facts & Figures. 2008
3. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol. 1989;7(9):1239–51. [PubMed]
4. American Cancer Society. Breast cancer facts & figures 2005-2006. Atlanta (GA): American. Cancer Society Inc. 2005
5. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S. Natural history of node-negative breast cancer: a study of 826 patients with longterm follow-up. J Clin Oncol. 1995;13(5):1144–51. [PubMed]
6. Rosen PP, Groshen S, Kinne DW. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow up study. J Clin Oncol. 1991;9(9):1650–61. [PubMed]
7. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120(2):104–10. [PubMed]
8. Rozenberg S, Antoine C, Carly B, Pastijn A, Liebens F. Improving quality of life after breast cancer: prevention of other diseases. Menopause Int. 2007;13(2):71–4. [PubMed]
9. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95(7):526–32. [PubMed]
10. Da cunha EFF, Martins RCA, Albuquerque MG, de Alecastro RB. LIV-3D-QSAR Model for Estrogen Receptor Ligands. J. Mol. model. 2004;10:297–304.
11. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science. 2002;296(5573):1642–4. [PubMed]
12. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev. 1999;20(3):321–44. [PubMed]
13. Kushner PJ, Agard DA, Greene GL, Scanlan T S, Shiau AK, Uht RM, Webb P. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 2000;74(5):311–7. [PubMed]
14. Watanabe T, Inoue S, Hiroi H, Orimo A, Kawashima H, Muramatsu M. Isolation of estrogen responsive genes with a CpG island library. Mol Cell Biol. 1998;18(1):442–9. [PMC free article] [PubMed]
15. Dubik D, Shiu RP. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene. 1992;7(8):1587–94. [PubMed]
16. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 2000;103(6):843–52. [PubMed]
17. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science. 2000;295(5564):2465–8. [PubMed]
18. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/ thyroid receptor superfamily members. Annu Rev Biochem. 1994;63:451–86. [PubMed]
19. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138(3):863–70. [PubMed]
20. Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer. 2006;6(5):360–8. [PubMed]
21. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995;270(5241):1491–4. [PubMed]
22. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. Cell. 1987;51(6):941–51. [PubMed]
23. Moras D, Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol. 1998;10(3):384–91. [PubMed]
24. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389(6652):753–8. [PubMed]
25. Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens. J Clin Oncol. 1997;15(2):840–52. [PubMed]
26. Harris HA, Albert MN, Leathurby Y, Malamas MS, Mewshaw RE, Miller CP, Kharode JP, Marzolf J, Komm BS, Winneker RC, Frail DE, Henderson RA, Zhu Y, Keith JC., Jr. Evaluation of an estrogen receptorß agonist in animal models of human disease. Endocrinology. 2003;144(10):4241–9. [PubMed]
27. Beato M, Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev. 1996;17(6):587–609. [PubMed]
28. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol. 1996;10(10):1167–77. [PubMed]
29. Glass CK, Rose DW, Rosenfeld MG. Nuclear receptor coactivators. Curr Opin Cell Biol. 1997;9(2):222–32. [PubMed]
30. Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ, West BL. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science. 1998;280(5370):1747–9. [PubMed]
31. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997;387(6634):733–6. [PubMed]
32. Russo IH, Russo J. Role of hormones in cancer initiation and progression. J Mammary Gland Biol Neoplasia. 1998;3(1):49–61. [PubMed]
33. Huang A, Kaley G. Gender-specific regulation of cardiovascular function: estrogen as key player. Microcirculation. 2004;11(1):9–38. [PubMed]
34. Riggs BL, Khosla S, Melton LJ., 3rd Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23(3):279–302. [PubMed]
35. Maggi A, Ciana P, Belcredito S, Vegeto E. Estrogens in the nervous system mechanisms and nonreproductive functions. Annu Rev Physiol. 2004;66:291–313. [PubMed]
36. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33. [PubMed]
37. Gehrig PA, Bae-Jump VL, Boggess JF, Groben PA, Fowler WC, Jr, Van Le L. Association between uterine serous carcinoma and breast cancer. Gynecol Oncol. 2004;94(1):208–11. [PubMed]
38. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A. WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausual women: the Women's Health Initiative randomized trial. JAMA. 2003;289(24):3243–53. [PubMed]
39. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1988;48(2):246–53. [PubMed]
40. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896;2:104–7.
41. Key TJ, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol. 1988;24(1):29–43. [PubMed]
42. Dorgan JF, Longcope C, Stephenson HE, Jr, Falk RT, Miller R, Franz C, Kahle L, Campbell WS, Tangrea JA, Schatzkin A. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1996;5(7):533–9. [PubMed]
43. Russo J, Hasan Lareef M, Balogh G, Guo S, Russo IH. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol. 2003;87(1):1–25. [PubMed]
44. Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan E G, Cavalieri EL. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol. 2003;86(3-5):477–86. [PubMed]
45. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators mechanisms of action and application to clinical practice. N Engl J Med. 2003;348(7):618–29. [PubMed]
46. Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G, Martini PG, McInerney EM, Delage-Mourroux R, Weis K, Katzenellenbogen JA. Estrogen receptors: Selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res. 2000;55:163–93. [PubMed]
47. McKenna NJ, O'Malley BW. An issue of tissues: divining the split personalities of selective estrogen receptor modulators. Nat Med. 2000;6(9):960–2. [PubMed]
48. Dowers TS, Qin ZH, Thatcher GR, Bolton JL. Bioactivation of Selective Estrogen Receptor Modulator (SERMs) Chem Res Toxicol. 2006;19(9):1125–37. [PMC free article] [PubMed]
49. Sharma M, Shubert DE, Lewis J, McGarrigle BP, Bofinger DP, Olson JR. Biotransformation of tamoxifen in a human endometrial explant culture model. Chem Biol Interact. 2003;146(3):237–49. [PubMed]
50. Fisher B, Redmond C. New perspective on cancer of the contralateral breast: A marker for assessing tamoxifen as a preventive agent 1991. J Natl Cancer Inst. 1991;83(18):1278–80. [PubMed]
51. Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971;25(2):270–5. [PMC free article] [PubMed]
52. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320(8):479–84. [PubMed]
53. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000. [PubMed]
54. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88. [PubMed]
55. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86(7):527–37. [PubMed]
56. Jordan VC. Tamoxifen: Toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol. 1995;35:195–211. [PubMed]
57. King CM. Tamoxifen and the induction of cancer. Carcinogenesis. 1995;16(7):1449–54. [PubMed]
58. Vancutsem PM, Lazarus P, Williams GM. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res. 1994;54(14):3864–7. [PubMed]
59. Fendl KC, Zimniski SJ. Role of tamoxifen in the induction of hormone-independent rat mammary tumors. Cancer Res. 1992;52(1):235–7. [PubMed]
60. Roos W, Oeze L, Loser R, Eppenberger U. Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7. J Natl Cancer Inst. 1983;71(1):55–9. [PubMed]
61. White IN, de Matteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, Phillips DH. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis. 1992;13(12):2197–203. [PubMed]
62. Pace P, Jarman M, Phillips D, Hewer A, Bliss J, Coombes RC. Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts. Br J Cancer. 1997;76(6):700–4. [PMC free article] [PubMed]
63. Kim SY, Suzuki N, Laxmi YR, Shibutani S. Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab Rev. 2004;36(2):199–218. [PubMed]
64. Johnston SR. Endocrine manipulation in advanced breast cancer: Recent advances with SERM therapies. Clin Cancer Res. 2001;7(12 Suppl):4376s–4387s. discussion 4411s-4412s. [PubMed]
65. Phillips C. STAR results: Raloxifene as effective as tamoxifen, better safety profile. NCI Cancer. 2006 Bulletin 3 1-2.
66. Gradishar W, Glusman J, Lu Y, Vogel C, Cohen FJ, Sledge GW., Jr Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer. 2000;88(9):2047–53. [PubMed]
67. McMeekin DS, Gordon A, Fowler J, Melemed A, Buller R, Burke T, Bloss J, Sabbatini P. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol. 2003;90(1):64–9. [PubMed]
68. Chan S. Arzoxifene in breast cancer. Eur J Cancer. 2002;38(Suppl 6):S55–6. [PubMed]
69. Thomas W, Burke MD, Walker CL. Arzoxifene as therapy for endometrial cancer. Gynecol Oncol. 2003;90(2 Pt 2):S40–6. [PubMed]
70. Suh N, Glasebrook AL, Palkowitz AD, Bryant HU, Burris LL, Starling JJ, Pearce HL, Williams C, Peer C, Wang Y, Sporn MB. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res. 2001;61(23):8412–5. [PubMed]
71. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. Natl Cancer Inst. 1973;51(5):1409–16.
72. Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, Mailhot J, Ouellet C, Schwerdtfeger A, Leblanc G, Martel C, Simard J, Merand Y, Belanger A, Labrie C, Labrie F. (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy] phenyl ]-2H-1- benzopyran-3-yl]phenyl 2,2-dimethylpropanoate (EM-800): A highly potent, specific, and orally active nonsteroidal antiestrogen. J Med Chem. 1997;40(14):2117–22. [PubMed]
73. Simard J, Labrie C, Belanger A, Gauthier S, Singh SM, Merand Y, Labrie F. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int J Cancer. 1997;73(1):104–12. [PubMed]
74. Simard J, Sanchez R, Poirier D, Gauthier S, Singh SM, Merand Y, Belanger A, Labrie C, Labrie F. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res. 1997;57(16):3494–7. [PubMed]
75. Bruno RD, Njar VC. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem. 2007;15(15):5047–60. [PMC free article] [PubMed]
76. Mastorakos G, Valsamakis G, Paltoglou G, Creatsas G. Management of obesity in menopause: Diet, exercise, pharmacotherapy and bariatric surgery. Maturitas. 2009 Dec 29;
77. Smith IE, Dowsett M. Aromatase Inhibitors in Breast Cancer. N Engl J Med. 2003;348(24):2431–42. [PubMed]
78. Goss PE, Strasser K. Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer. J Clin Oncol. 2001;19(3):881–94. [PubMed]
79. Geisler J, Lien EA, Ekse D, Lonning PE. Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrostenedione sulphate in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol. 1997;63(1-3):53–8. [PubMed]
80. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131–9. [PubMed]
81. Turner RT, Wakley GK, Hannon KS, Bell NH. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res. 1987;2(5):449–56. [PubMed]
82. Arnett TR, Lindsay R, Kilb JM, Moonga BS, Spowage M, Dempster DW. Selective toxic effects of tamoxifen on osteoclasts: comparison with the effects of oestrogen. J Endocrinol. 1996;149(3):503–8. [PubMed]
83. Wright CD, Garrahan NJ, Stanton M, Gazet JC, Mansell RE, Compston JE. Effect of long-term tamoxifen therapy on cancellous bone remodeling and structure in women with breast cancer. J Bone Miner Res. 1994;9(2):153–9. [PubMed]
84. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14(1):78–84. [PubMed]
85. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol. 2006;24(4):675–80. [PubMed]
86. Eng-Wong J, Reynolds JC, Venzon D, Liewehr D, Gantz S, Danforth D, Liu ET, Chow C, Zujewski J. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab. 2006;91(10):3941–6. [PubMed]
87. Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN, Transbøl I, Mouridsen HT. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol. 1994;12(5):992–7. [PubMed]
88. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326(13):852–6. [PubMed]
89. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med. 1995;99(6):636–41. [PubMed]
90. Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med. 1994;154(22):2585–8. [PubMed]
91. Kristensen B, Ejlertsen B, Mouridsen HT, Andersen KW, Lauritzen JB. Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat. 1996;39(3):321–6. [PubMed]
92. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N.Engl.J.Med. 1997;337:1641–1647. [PubMed]
93. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. - Results from a 3-year randomized clinical trial. JAMA. 1999;282:637–645. [PubMed]
94. Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone. 2003;33:522–532. [PubMed]
95. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD. MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four-years results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287:847–857. [PubMed]
96. Eastell R, Hannon R. Long-term effects of aromatase inhibitors on bone. J Steroid Biochem Mol Biol. 2005;95(1-5):151–4. [PubMed]
97. Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab. 1998;83(7):2239–43. [PubMed]
98. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002;95(9):2006–16. [PubMed]
99. Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchencko M, Boyce SP, Mallett D, Perez EA. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer. 2006;7(2):127–32. [PubMed]
100. Carney JF, Davis J. Emerging bone health issues in women with breast cancer in Hawai’i. Hawaii Med J. 2007;66(6):164–6. [PubMed]
101. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–2. [PubMed]
102. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53. [PubMed]
103. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J. ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366(9484):455–62. [PubMed]
104. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. ATAC Trialists' group. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial. J Bone Miner Res. 2006;21(8):1215–23. [PubMed]
105. Coleman RE. Group AT: Effect of anastrozole on bone mineral density: 5-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol. 2006;24(5s suppl) (abstr 511)
106. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von Minckwitz G. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 study. J Clin Oncol. 2007;25(19):2664–70. [PubMed]
107. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P. Switching to anastrozole versus continued tamoxifene treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23(22):5138–47. [PubMed]
108. Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol. 2008;26(33):5465–76. [PubMed]
109. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol. 2007;25(5):486–92. [PubMed]
110. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–71. [PubMed]
111. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24(22):3629–35. [PubMed]
112. Goss PE, Qi S, Josse RG, Pritzker KP, Mendes M, Hu H, Waldman SD, Grynpas MD. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone. 2004;34(3):384–92. [PubMed]
113. Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KP. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res. 2004;10(17):5717–23. [PubMed]
114. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM. Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet. 2007;369(9561):559–70. [PubMed]
115. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC. Intergroup Exemestane Study group. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol. 2007;8(2):119–27. [PubMed]
116. Asmar L, Negron A, Stokoe C, et al. The effect of tamoxifen or exemestane on bone mineral density after 2 years of adjuvant treatment of postmenopausal women with early breast cancer.. 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX. December 14-17, 2006.
117. Gonnelli S, Cadirni A, Caffarelli C, Petrioli R, Montagnani A, Franci MB, Lucani B, Francini G, Nuti R. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone. 2007;40(1):205–10. [PubMed]
118. Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE, Polli A, di Salle E, Paolini J. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. Eur J Cancer. 2006;42(17):2968–75. [PubMed]
119. Compston JE. Sex steroids and bone. Physiol Rev. 2001;81:419–47. [PubMed]
120. Zapantis G, Santoro N. The menopausal transition: characteristics and management. Best Pract Res Clin Endocrinol Metab. 2003;17:33–52. [PubMed]
121. Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res. 2007;9(4):R52. [PMC free article] [PubMed]
122. Hadji P, Ziller M, Kieback DG, Menschik T, Kalder M, Kuck J, Hasenburg A. The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Breast. 2009;18(3):159–64. [PubMed]
123. Chang J, Powles TJ, Ashley SE, Gregory RK, Tidy VA, Treleaven JG, Singh R. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol. 1996;7(7):671–675. [PubMed]
124. Seeman E. Pathogenesis of bone fragility in women and men. Lancet. 2002;359:1841–1850. [PubMed]
125. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of theSurgical Adjuvant Breast and Bowel Project P 1 study. J Natl Cancer Inst. 2005;97(22):1652–1662. [PubMed]
126. McCaig Fiona M, Renshaw Lorna, Williams Linda, Young Oliver, Murray Juliette, Macaskill Elizabeth J., McHugh Mary, Hannon Rosemary, Dixon J. Michael. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2010;119(3):643–51. [PubMed]
127. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC. Intergroup Exemestane Study group. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study: a randomized controlled study. Lancet Oncol. 2007;8(2):119–27. [PubMed]
128. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53. [PubMed]
129. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. NEJM. 2002;346(9):653–61. [PubMed]
130. Greep NC, Giuliano AE, Hansen NM, Taketani T, Wang HJ, Singer FR. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med. 2003;114(8):653–9. [PubMed]
131. Van Poznak C, Hannon R, Clack G, et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis. Breast Cancer Res Treat. 2007;106:502.
132. Lester JE, Gutcher SA, Ellis SP, et al. Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One-year results from the ARIBON study. J Clin Oncol. 2007;25:16s. (suppl; abstr 553)
133. Greenspan SL, Bhattacharya RK, Sereika SM, Brufsky A, Vogel VG. Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebocontrolled clinical trial. J Clin Endocrinol Metab. 2007;92(1):131–6. [PubMed]
134. Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early stage breast cancer. J Clin Oncol. 2008;26(29):4739–45. [PMC free article] [PubMed]
135. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebocontrolled study. J Clin Oncol. 1997;15(3):955–62. [PubMed]
136. Fuleihan Gel-H, Salamoun M, Mourad YA, Chehal A, Salem Z, Mahfoud Z, Shamseddine A. Pamidronate in the prevention of chemotherapy induced bone loss in premenopausal women with breast cancer: A randomized controlled trial. J Clin Endocrinol Metab. 2005;90(6):3209–14. [PubMed]
137. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R. Austrian Breast and Colorectal Cancer Study Group. Zoledronic acid prevents cancer treatment induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25(7):820–8. [PubMed]
138. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Bone mineral density (BMD) at 5 years after diagnosis in premenopausal patients with endocrine responsive breast cancer, after 3 years of adjuvant endocrine treatment with goserelin and tamoxifen or anastrozole or both treatments in combination with zoledronic acid: New results from ABCSG-12.; 30th Annual San Antonio Breast Cancer Symposium. San Antonio, TX. December 13-16, 2007; (abstr 26)
139. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25(7):829–36. [PubMed]
140. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA. The effect of zoledronic acid on aromatase-inhibitor associated bone loss in postmenopausal women with early breast cancer reciving adjuvant letrozole: The Z-FAST study 36 month follow-up. Clin Breast Cancer. 2009;9(2):77–85. [PubMed]
141. Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE. Effective inhibition of aromatase inhibitor associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer. 2008;112(5):1001–10. [PubMed]
142. De Boer R, Eidtmann H, Lluch A, et al. The ZO-FAST trial: Zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24 month BMD results. Breast Cancer Res Treat. 2007;106:501.
143. Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikcevich DA, Loprinzi CL. Immediate vs. delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen N03CC. Breast Cancer Res Treat. 2009;117(3):603–9. [PubMed]
144. Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy PS, Dalton RJ, Mattar BI, Loprinzi CL. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast. 2010
145. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM. Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women. Results From the National Osteoporosis Risk Assessment. JAMA. 2001;286(22):2815–22. [PubMed]
146. Smith DM, Nance WE, Kang KW, Christian JC, Johnston CC., Jr Genetic factors in determining bone mass. J Clin Invest. 1973;52(11):2800–8. [PMC free article] [PubMed]
147. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S. Genetic determinants of bone mass in adults. A twin study. J Clin Invest. 1987;80(3):706–10. [PMC free article] [PubMed]
148. Mundy GR. Osteoporosis. Boning up on genes. Nature. 1994;367:216–7. [PubMed]
149. Kelly PJ, Hopper JL, Macaskill GT, Pocock NA, Sambrook PN, Eisman JA. Genetic factors in bone turnover. J Clin Endocrinol Metab. 1991;72(4):808–13. [PubMed]
150. Steward TL, Ralston SH. Role of genetic factors in the pathogenesis of osteoporosis. Journal of Endocrinology. 2000;166:235–45. [PubMed]
151. Seeman E, Hopper JL, Bach LA, Cooper ME, Parkinson E, McKay J, Jerums G. Reduced bone mass in daughters of women with osteoporosis. N Engl J Med. 1989;320(9):554–8. [PubMed]
152. Hansen MA, Hassager C, Jensen SB, Christiansen C. Is heritability a risk factor for postmenopausal osteoporosis? J Bone Miner Res. 1992;7(9):1037–43. [PubMed]
153. Christian JC, Yu PL, Slemenda CW, Johnston CC., Jr Heritability of bone mass: a longitudinal study in aging male twins. Am J Hum Genet. 1989;44(3):429–33. [PMC free article] [PubMed]
154. Harris M, Nguyen TV, Howard GM, Kelly PJ, Eisman JA. Genetic and environmental correlations between bone formation and bone mineral density: a twin study. Bone. 1998;22(2):141–5. [PubMed]
155. Adami S, Bertoldo F, Brandi ML, Cepollaro C, Filipponi P, Fiore E, Frediani B, Giannini S, Gonnelli S, Isaia GC, Luisetto G, Mannarino E, Marcocci C, Masi L, Mereu C, Migliaccio S, Minisola S, Nuti R, Rini G, Rossini M, Varenna M, Ventura L, Bianchi G. Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo. 2009;61(4):260–84. [PubMed]
156. Bottorff Joan L., McKeown Stephanie Barclay, Carey Joanne, Haines Rebecca, Okoli Chizimuzo, Johnson Kenneth C., Easley Julie, Ferrence Roberta, Baillie Lynne, Ptolemy Erin. Young women's responses to smoking and breast cancer risk information. Health Educ Res. 2010 Jan 15;
157. Fontana L, Shew JL, Holloszy JO, Villareal DT. Low bone mass in subjects on a long-term raw vegetarian diet. Arch Intern Med. 2005;165(6):684–9. [PubMed]
158. Health Evidence Bulletins Wales. Oteoporosis. Cardiff: National Assembly for Wales 2001.
159. Bruyere O, Edwards J, Reginster J-Y. Fracture prevention in postmenopausal women. Clin Evid. 2005;13:1419–34. [PubMed]
160. Patterson RE, Flatt SW, Saquib N, Rock CL, Caan BJ, Parker BA, Laughlin GA, Erickson K, Thomson CA, Bardwell WA, Hajek RA, Pierce JP. Medical comorbidities predict mortality in women with a history of early stage breast cancer. Breast Cancer Res Treat. 2010 Jan 14;
161. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785–95. [PubMed]
162. WHO Study Group Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129. [PubMed]
163. Gehlbach SH, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood JR. Recognition of vertebral fracture in a clinical setting. Osteoporos Int. 2000;11(7):577–82. [PubMed]
164. Jiang Y, Zhao J, Augat P, Ouyang X, Lu Y, Majumdar S, Genant HK. Trabecular bone mineral and calculated structure of human bone specimens scanned by peripheral quantitative computed tomography: relation to biomechanical properties. J Bone Miner Res. 1998;13(11):1783–90. [PubMed]
165. Hans D, Njeh CF, Genant HK, Meunier PJ. Quantitative ultrasound in bone status assessment. Rev Rhum Engl Ed. 1998;65(7-9):489–98. [PubMed]
166. Seeman E, Hopper JL, Bach LA, Cooper ME, Parkinson E, McKay J, Jeremus G. Reduced bone mass in daughters of women with osteoporosis. N Engl J Med. 1989;320:554–558. [PubMed]
167. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet. 1995;59:97–105. [PubMed]
168. Siegelmann-Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer. 1999;79(3-4):456–63. [PMC free article] [PubMed]
169. Masi L, Becherini L, Gennari L, Amedei A, Colli E, Falchetti A, Farci M, Silvestri S, Gonnelli S, Brandi ML. Polymorphism of the Aromatase Gene in Postmenopausal Italian Women: Distribution and Correlation with Bone Mass and Fracture Risk. J Clin Endocrinol Metab. 2001;80:3689–98.
170. Gennari L, Masi L, Merlotti D, Picariello L, Falchetti A, Tanini A, Mavilia C, Del Monte F, Gonnelli S, Lucani B, Gennari C, Brandi ML. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab. 2004;89:2803–10. [PubMed]
hormoontherapie, Arimidex, tamoxifen, borstkanker, anastrozole, letrozole, femara
Gerelateerde artikelen
Plaats een reactie ...
Reageer op "Overzichtsartikel over hormoonblokkers en aromaseremmers toegevoegd."